This is not the most recent version of the article. View current version (9 NOV 2011)

Intervention Protocol

Antiplatelet agents for intermittent claudication

  1. Peter Robless1,*,
  2. Dimitris P Mikhailidis2,
  3. Gerard P Stansby3

Editorial Group: Cochrane Peripheral Vascular Diseases Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD001272

Database Title

Additional Information

How to Cite

Robless P, Mikhailidis DP, Stansby GP. Antiplatelet agents for intermittent claudication (Protocol). Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD001272. DOI: 10.1002/14651858.CD001272.

Author Information

  1. 1

    Yong Loo Lin School of Medicine, National University of Singapore, Department of Cardiac, Thoracic and Vascular Surgery, Singapore, Singapore

  2. 2

    Royal Free and University College Medical School, Department of Clinical Biochemistry, London, UK

  3. 3

    University of Newcastle upon Tyne, Department of Surgery, Newcastle upon Tyne, UK

*Peter Robless, Department of Cardiac, Thoracic and Vascular Surgery, Yong Loo Lin School of Medicine, National University of Singapore, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore. surrpa@nus.edu.sg. peter_robless@btopenworld.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

This is not the most recent version of the article.View current version (09 Nov 2011)

View Full Article (HTML) Full (91K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary aim will be to determine the effect of antiplatelet agents in reducing vascular mortality and cardiovascular events (myocardial infarction and stroke) in patients with stable intermittent claudication (Fontaine stage II) (Fontaine 1954).

In addition, where data exists, the efficacy of antiplatelet agents in reducing total mortality, improving ankle brachial pressure index, improving treadmill walking distance, preventing progression to surgery, benefits on quality of life, and side effects of these drugs will be assessed.

View Full Article (HTML) Full (91K)